The worldwide incidence of diabetes has been increasing markedly, and by 2014 it had increased to 422 million individuals from 108 million only 34 years previously.
With the recent surge in artificial intelligence (AI) and machine learning, ophthalmology is already seeing the benefits.
When it comes to questions about the need for laser in diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR), the answers are “yes” and “no,” depending on the clinical scenario, said John Wells, MD.
Anti-vascular endothelial growth factor (VEGF) therapy is a viable alternative to panretinal photocoagulation (PRP) in eyes with proliferative diabetic retinopathy (PDR).
Quiescence, steroid-free quiescence achieved in VISUAL III trial
Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder
Cataract surgery should not be delayed based on the HbA1c levels in patients with diabetic eye disease.
Myopic traction maculopa (MTM) and macular hole retinal detachments (MHRDs) are complex scenarios that demand accurate diagnoses and high surgical expertise.
What's in a name? When it comes to ophthalmology, a lot. Persistent hyperplastic primary vitreous—an old name that addressees only the status of the primary vitreous—needs updating, said Michael Trese, MD.
First-line treatment for diabetic macular edema (DME) is overwhelmingly anti-vascular endothelial growth factor (VEGF) drugs, with more than two-thirds of clinicians around the world prescribing them for this patient population.